Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy
(IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer.
Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and
shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.